You just read:

Daiichi Sankyo Initiates Two Phase 3 Trials of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Positive Metastatic Breast Cancer including Head-to-Head Versus T-DM1 and Post-T-DM1 Study

News provided by

Daiichi Sankyo Company, Limited

25 Sep, 2018, 13:00 BST